A Phase 1/2 Study of INCB000928 as Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104)

被引：0
|
作者：
Oh, Stephen [1 ]
Kiladjian, Jean-Jacques [2 ]
Palandri, Francesca [3 ]
Gotlib, Jason [4 ]
Mohan, Sanjay [5 ]
Ali, Haris [6 ]
Asatiani, Ekatherine [7 ]
Seguy, Francis [7 ]
Zhou, Feng [8 ]
Verstovsek, Srdan [9 ]
机构：
[1] Washington Univ, Sch Med, St Louis, MO USA
[2] Univ Paris, INSERM, Hop St Louis, AP HP, Paris, France
[3] Azienda Osped Univ Bologna, IRCCS Ist Ricovero & Cura Carattere Sci, Policlin S Orsola Malpighi, Bologna, Italy
[4] Stanford Canc Inst, Stanford, CA USA
[5] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[6] City Hope Med Ctr, Duarte, CA USA
[7] Incyte Biosci Int Sarl, Morges, Switzerland
[8] Incyte Corp, Wilmington, DE USA
[9] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2021年 / 193卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH2021-PO
引用
收藏
页码：111 / 112
页数：2
相关论文
共 50 条
  • [21] Updated results from a phase 1/2 study of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma
    Gibney, G.
    Hamid, O.
    Lutzky, J.
    Olszanski, A.
    Gangadhar, T.
    Gajewski, T.
    Chmielowski, B.
    Hanks, B.
    Boasberg, P.
    Zhao, Y.
    Newton, R.
    Bowman, J.
    Maleski, J.
    Leopold, L.
    Weber, J. S.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S106 - S107
  • [22] Phase 2 study of ruxolitinib in combination with 5-azacitidine in patients with myelofibrosis.
    Masarova, Lucia
    Cortes, Jorge E.
    Pemmaraju, Naveen
    Jabbour, Elias
    Bose, Prithviraj
    Ohanian, Maro
    Zhou, Lingsha
    Pierce, Sherry
    Gergis, Romany
    Borthakur, Gautam
    Estrov, Zeev
    Garcia-Manero, Guillermo
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    Daver, Naval Guastad
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [23] Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis
    Harrison, Claire N.
    Garcia, Jacqueline S.
    Mesa, Ruben A.
    Somervaille, Tim C. P.
    Komrokji, Rami S.
    Pemmaraju, Naveen
    Jamieson, Catriona
    Papadantonakis, Nikolaos
    Foran, James M.
    O'Connell, Casey L.
    Holes, Leanne
    Jia, Jia
    Harb, Jason
    Hutti, Jessica
    Prchal, Josef T.
    BLOOD, 2019, 134
  • [24] Updated Results of Phase 2 Study of Ruxolitinib in Combination with 5-Azacitidine in Patients with Myelofibrosis
    Masarova, Lucia
    Verstovsek, Srdan
    Cortes, Jorge E.
    Pemmaraju, Naveen
    Bose, Prithviraj
    Ohanian, Maro N.
    Zhou, Lingsha
    Pierce, Sherry A.
    Gergis, Romany
    Borthakur, Gautam
    Estrov, Zeev E.
    Garcia-Manero, Guillermo
    Kantarjian, Hagop M.
    Daver, Naval G.
    BLOOD, 2018, 132
  • [25] Updated Results of a Phase 2 Study of Ruxolitinib in Combination With 5-Azacitidine in Patients With Myelofibrosis
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (01) : 12 - 13
  • [26] Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study
    Sorensen, Anders Lindholm
    Mikkelsen, Stine Ulrik
    Knudsen, Trine Alma
    Bjorn, Mads Emil
    Andersen, Christen Lykkegaard
    Bjerrum, Ole Weis
    Brochmann, Nana
    Patel, Dustin Andersen
    Gjerdrum, Lise Mette Rahbek
    El Fassi, Daniel
    Kruse, Torben A.
    Larsen, Thomas Stauffer
    Mourits-Andersen, Hans Torben
    Nielsen, Claus Henrik
    Ellervik, Christina
    Pallisgaard, Niels
    Thomassen, Mads
    Kjaer, Lasse
    Skov, Vibe
    Hasselbach, Hans Carl
    HAEMATOLOGICA, 2020, 105 (09) : 2262 - 2272
  • [27] Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis
    Masarova, Lucia
    Verstovsek, Srdan
    Bose, Prithviraj
    Pemmaraju, Naveen
    Cortes, Jorge E.
    Jabbour, Elias
    Ohanian, Maro
    Zhou, Lingsha
    Pierce, Sherry A.
    Gergis, Romany
    Borthakur, Gautam M.
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Ravandi, Farhad
    Konopleva, Marina Y.
    Naqvi, Kiran
    Sasaki, Koji
    Estrov, Zeev E.
    Garcia-Manero, Guillermo
    Bueso-Ramos, Carlos E.
    Kantarjian, Hagop M.
    Daver, Naval G.
    BLOOD, 2019, 134
  • [28] Preliminary safety and efficacy data from a phase 1/2 study of epacadostat (INCB024360) in combination with pembrolizumab in patients with advanced/metastatic melanoma
    Gajewski, Thomas F.
    Hamid, Omid
    Smith, David C.
    Bauer, Todd M.
    Wasser, Jeffrey S.
    Luke, Jason J.
    Balmanoukian, Ani S.
    Kaufman, David R.
    Zhao, Yufan
    Maleski, Janet
    Leopold, Lance
    Gangadhar, Tara C.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2016, 14
  • [29] Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study
    Francisco Cervantes
    David M. Ross
    Atanas Radinoff
    Francesca Palandri
    Alexandr Myasnikov
    Alessandro M. Vannucchi
    Pierre Zachee
    Heinz Gisslinger
    Norio Komatsu
    Lynda Foltz
    Francesco Mannelli
    Francesco Passamonti
    Geralyn Gilotti
    Islam Sadek
    Ranjan Tiwari
    Evren Zor
    Haifa Kathrin Al-Ali
    Leukemia, 2021, 35 : 3455 - 3465
  • [30] A PHASE 1 STUDY OF PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH A PI3K DELTA INHIBITOR (INCB040093) ALONE OR IN COMBINATION WITH A SELECTIVE JAK1 INHIBITOR (INCB039110)
    Forero-Torres, A.
    Barr, P.
    Diefenbach, C.
    Sher, T.
    Schaub, R.
    Zhou, L.
    Pulini, J.
    Leopold, L.
    Spear, M.
    Talpaz, M.
    Phillips, T.
    HAEMATOLOGICA, 2015, 100 : 112 - 112
12345